Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
ACS Med Chem Lett ; 12(4): 563-571, 2021 Apr 08.
Article in English | MEDLINE | ID: mdl-33859796

ABSTRACT

This study evaluated the potential use of senescence-inducing small molecules in the treatment of melanoma. We screened commercially available small-molecule libraries with high-throughput screening and high-content screening image-based technology. Our findings showed an initial hit with the embedded N-arylpiperidine-3-carboxamide scaffold-induced senescence-like phenotypic changes in human melanoma A375 cells without serious cytotoxicity against normal cells. A focused library containing diversely modified analogues were constructed and examined to evaluate the structure-activity relationship of N-arylpiperidine-3-carboxamide derivatives starting from hit 1. This work identified a novel compound with remarkable antiproliferative activity in vitro and demonstrated the key structural moieties within.

2.
Eur J Med Chem ; 209: 112550, 2021 Jan 01.
Article in English | MEDLINE | ID: mdl-33268144

ABSTRACT

Current research suggests therapy-induced senescence (TIS) of cancer cells characterized by distinct morphological and biochemical phenotypic changes represent a novel functional target that may enhance the effectiveness of cancer therapy. In order to identify novel small-molecule inducers of cellular senescence and determine the potential to be used for the treatment of melanoma, a new method of high-throughput screening (HTS) and high-contents screening (HCS) based on the detection of morphological changes was designed. This image-based and whole cell-based technology was applied to screen and select a novel class of antiproliferative agents on cancer cells, 4H-chromeno[2,3-d]pyrimidin-4-one derivatives, which induced senescence-like phenotypic changes in human melanoma A375 cells without serious cytotoxicity against normal cells. To evaluate structure-activity relationship (SAR) study of 4H-chromeno[2,3-d]pyrimidin-4-one scaffold starting from hit 3, a focused library containing diversely modified analogues was constructed and which led to the identification of 38, a novel compound to have remarkable anti-melanoma activity in vitro with good metabolic stability.


Subject(s)
Antineoplastic Agents/pharmacology , Benzopyrans/pharmacology , Cell Proliferation/drug effects , Cellular Senescence/drug effects , Melanoma/drug therapy , Pyrimidines/pharmacology , Animals , Antineoplastic Agents/chemistry , Benzopyrans/chemistry , Cell Line, Tumor , Drug Screening Assays, Antitumor , Humans , Male , Melanoma/pathology , Mice, Inbred BALB C , Pyrimidines/chemistry
3.
J Biol Chem ; 289(21): 15094-103, 2014 May 23.
Article in English | MEDLINE | ID: mdl-24692554

ABSTRACT

More than 100 copper/zinc superoxide dismutase 1 (SOD1) genetic mutations have been characterized. These mutations lead to the death of motor neurons in ALS. In its native form, the SOD1 protein is expressed as a homodimer in the cytosol. In vitro studies have shown that SOD1 mutations impair the dimerization kinetics of the protein, and in vivo studies have shown that SOD1 forms aggregates in patients with familial forms of ALS. In this study, we analyzed WT SOD1 and 9 mutant (mt) forms of the protein by non-invasive fluorescence techniques. Using microscopic techniques such as fluorescence resonance energy transfer, fluorescence complementation, image-based quantification, and fluorescence correlation spectroscopy, we studied SOD1 dimerization, oligomerization, and aggregation. Our results indicate that SOD1 mutations lead to an impairment in SOD1 dimerization and, subsequently, affect protein aggregation. We also show that SOD1 WT and mt proteins can dimerize. However, aggregates are predominantly composed of SOD1 mt proteins.


Subject(s)
Amyotrophic Lateral Sclerosis/enzymology , Liver/enzymology , Mutation , Protein Multimerization , Superoxide Dismutase/chemistry , Superoxide Dismutase/genetics , Fluorescence Resonance Energy Transfer , HEK293 Cells , Humans , Liver/cytology , Luminescent Proteins/genetics , Luminescent Proteins/metabolism , Microscopy, Confocal , Models, Molecular , Mutant Proteins/chemistry , Mutant Proteins/genetics , Protein Structure, Quaternary , Spectrometry, Fluorescence , Superoxide Dismutase-1
4.
J Biomol Screen ; 15(7): 847-57, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20639502

ABSTRACT

Advances in automated imaging microscopy allow fast acquisitions of multidimensional biological samples. Those microscopes open new possibilities for analyzing subcellular structures and spatial cellular arrangements. In this article, the authors describe a 3D image analysis framework adapted to medium-throughput screening. Upon adaptive and regularized segmentation, followed by precise 3D reconstruction, they achieve automatic quantification of numerous relevant 3D descriptors related to the shape, texture, and fluorescence intensity of multiple stained subcellular structures. A global analysis of the 3D reconstructed scene shows additional possibilities to quantify the relative position of organelles. Implementing this methodology, the authors analyzed the subcellular reorganization of the nucleus, the Golgi apparatus, and the centrioles occurring during the cell cycle. In addition, they quantified the effect of a genetic mutation associated with the early onset primary dystonia on the redistribution of torsinA from the bulk endoplasmic reticulum to the perinuclear space of the nuclear envelope. They show that their method enables the classification of various translocation levels of torsinA and opens the possibility for compound-based screening campaigns restoring the normal torsinA phenotype.


Subject(s)
Automation/methods , High-Throughput Screening Assays/methods , Imaging, Three-Dimensional/methods , Organelles/metabolism , Animals , Cell Cycle , Cell Nucleus/metabolism , Dystonic Disorders/diagnosis , HeLa Cells , Humans , Mice , Models, Biological , Molecular Chaperones/metabolism , Subcellular Fractions/metabolism
5.
Chem Commun (Camb) ; (16): 1910-2, 2008 Apr 28.
Article in English | MEDLINE | ID: mdl-18401515

ABSTRACT

Ni-nitrilotriacetic acid (NTA) functionalized CdSe/ZnS quantum dots (QDs) were exploited as a site-specific labeling agent of histidine-tagged biomolecules in live cells; the QDs were found to be water-soluble, aggregation free and stable for several months.


Subject(s)
Fluorescent Dyes/chemistry , Fluorescent Dyes/pharmacology , Histidine/chemistry , Nickel/chemistry , Nitrilotriacetic Acid/chemistry , Proteins/chemistry , Quantum Dots , Staining and Labeling/methods , Cell Line , Cell Survival/drug effects , Humans
6.
Biochem Biophys Res Commun ; 314(2): 646-53, 2004 Feb 06.
Article in English | MEDLINE | ID: mdl-14733956

ABSTRACT

Eotaxin selectively binds CC chemokine receptor (CCR) 3, whereas monocyte chemotactic protein (MCP)-3 binds CCR1, CCR2, and CCR3. To identify the functional determinants of the chemokines, we generated four reciprocal chimeric chemokines-M10E9, M22E21, E8M11, and E20M23-by shuffling the N-terminus and N-loop of eotaxin and MCP-3. M22E21 and E8M11, which shared the N-loop from MCP-3, bound to monocytes with high affinity, and activated monocytes. In contrast, M10E9 and E20M23, which lacked the N-loop, failed to bind and transduce monocyte responses, identifying the N-loop of MCP-3 as the selectivity determinant for CCR1/CCR2. A BIAcore assay with an N-terminal peptide of CCR3 (residues 1-35) revealed that all chimeras except E20M23 exhibited varying degrees of binding affinity with commensurate chemotaxis activity of eosinophils. Surprisingly, E20M23 could neither bind the CCR3 peptide nor activate eosinophils, despite having both N-terminal motifs from eotaxin. These results suggest that the two N-terminal motifs of eotaxin must cooperate with other regions to successfully bind and activate CCR3.


Subject(s)
Chemokines, CC/physiology , Cytokines , Monocyte Chemoattractant Proteins/physiology , Amino Acid Sequence , Calcium/metabolism , Chemokine CCL11 , Chemokine CCL7 , Chemotaxis , Dose-Response Relationship, Drug , Eosinophils/metabolism , Escherichia coli/metabolism , Humans , Inhibitory Concentration 50 , Kinetics , Molecular Sequence Data , Monocyte Chemoattractant Proteins/metabolism , Monocytes/metabolism , Peptides/chemistry , Protein Binding , Protein Serine-Threonine Kinases/metabolism , Protein Structure, Secondary , Protein Structure, Tertiary , Receptors, CCR2 , Receptors, CCR3 , Receptors, Chemokine/metabolism , Recombinant Fusion Proteins/metabolism , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...